Creatine Transporter Deficiency

Montana is pushing an experimental-drug regime with a $12,500 review-fee for companies to obtain approval to sell drugs via clinics, potentially turning the state into an experimental-medical hub by year-end, amid ethical and safety questions.

Montana’s expanded right-to-try framework creates an experimental-access pathway for unapproved CTD treatments like Ceres’ nasal spray, but FDA alignment and timing risks remain.